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Dala show h'lat r.~t dose ol 10 mg NIC emptied s~mficant clmtdalory 
eltects Ira- at leas1 up to 8 houm b~ me peak ~,',~ct and du~a~ o~ effec~ 
m~re ~ ammuam~ am~ re~ea~m ~.  Thos. ~ ~o pmra~ 
v~ew, ll~s sludy shows that c ~  torrance dm¢=k~ps fogom~g ~ 
eq~sme to ntcorandd. 
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Rece~ ~ have shown ltmt ~ use of mannttot may mcm~se renal o~t- 
ge~ demands, and deslm~, causing an osmot¢ diurems, may be ,n]u.ou~ to 
renal ~ after vascular contrast exposure. It's use. ~-=mfom, as a l~ro- 
phytact¢ agent to prevent contrast ~ t h y  after coronary 
remains controvers,~. As part of the PRINCE (Prmmr~r~n of Rad~K:ormast 
Induced Nephropathy Evaluat~0n) Tnal. palmnts ~ were ~ to a 
forced dmmsLs protocol (fumsemide I mg/kg WP and dopamme 3.g/kg/mm 
IV) and had a mean pulmooary capdla~ wedge pmssu~ <20 mmHg at the 
sta~ ot the procedure, received intravenous marmitol 12.5 oj1~g over 2 I'mum 
This administmtmn occurred clunng ~e conlrasl exposure and was foffo~ed 
by Ii~lrahon with 0.5 NS IV at a rato to match the urine oulput. As dictated by 
the protocol, those who were selected for mam,lol had a k~er mean PCWP. 
14.4 vs. 26.1 mmHg. p = 0.0009. The mean baseline serum c1"eatimne (Cr) 
was 2.2 ± 0.38 vs. 2.59 ± 0.94 in the mannttokexpased (groc~ 1, n = 22) vs. 
the mannitol-unexposed (group 2. n = 76), p = 0.05. Groups 1 and 2 were 
othe~rise sin~lar with respect to confotmdem including diabetic status and 
contrast volume received. The mean induced urine flow rates were 167.62 
± 58.00 vs. 133.20 ± 55.63 mYmin/over 24 hours, p = 0.02, in groups 1 and 
2 r e ~ .  The resultant mean Cr at 48 houm after contrast exposure 
was 2.72 ~ 1.19 vs. 3.11 ± 1.21 mg/dl, p = 0.22, and the mean ~ 1  
increase in Cr was 0.61 ± 0.98 vs. 0.58 ± 0.72 mg/dl, p = 0.88, respectrvely. 
Conclusions: Despite its use in patients with mote favorable renal funchon 
and hemodyrmmic profiles, the controlled, pmspectnte IV administration of 
mannitol was not effectwe in preventing renal injury despite augmentato'~ of 
a forced diuresis with other agents. 
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Recent studies from series of PTCA and CABG patients indicate that baseline 
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It has been m¢~,~-y ~ed thai CHF pa~e~s mm~d ~ car~lo l  have 
s~j~mr~y _r,~,___,c.~__ cmmmm~g ,~-~I  (ET-~) ~ as compared to 
~mm~ed mments. The m~c~ms m p~sma ET-I k.,e*s cormmnmU 
~th a ~ ~ ~ in va~m~ immmemm uud to mea- 
sure the ~ ~ ~ of head P=tiiurB. ~ ,  the f1~ch~-~i~.T~ 
for the ciecmase rn ET-1 was not known Tt-¢=~fore, rne f,,-=s~ s~,~'y was 
des-~g~..d to ~ me d~mct effects of cen~d~m* on ET-I 
5~S in ct.d~fed ~ corollary ~f1~ erl~0~hellal ~ (HCAECs). HCAECa 
were tmaP~J w~h canmd~lol 15 rmn Ire'lot o file ado~itlon of see.~n and ET-1 
levels were measured in the ~.~.~;;~..,,~,.~ mlmlnJ, m 24 hr later. ~ Ira> 
a ~ !  ml~mn of r, emm-med~ 
of ET-I bmsyne~ms ,~th an tC~ = i uM. Pm1~roE'r-1 mRNA e~easmn 
was also mhil~ted by carvedlol maln~nL Oe~r p -adnmo,~v~v a~ago~sls 
such as proprar~ol (10 uM) o~ ce~pm~ol (10 uM) did no~ effect ET.1 
thess. Fu'~e~mmo~, me amh~,~ant IXObUO~ (10 uM) ~ not enect ET-1 
product~n, fo'~muno-hisfochE~cel analys~ of HCAECs silo demonstmtsd 
b~at cenmd~of mh;b;h~3 ET-1 ~ .  These data ~te  thal cenm~Iof 
o~rec~ mhil~s me Im)syne~,s of ET-I in HCAECs, and this effect may 
con1~Imle to its ~,a;.-.;~lat mg and anlqamlifmaftve actions. Fmlhermom. these 
effects may contnbum to the ab~ltty of cantedilof to improve dtnlcal outcome 
in CHF paftents. 
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Canmdilol [C] is a multiactiog ant]hypertenshte drug recently also apf~oved 
for the treatment of heart failure and combines ~- with a~.bloCking and an- 
tioxidant activities. It was shown that C protects the vasculalum from chronic 
pathological processes such as ischemia, atherosck~osts and remodelling 
that is observed in the cardiovascular system after pressure overload and 
shear stress. To evaluate the antiproliferatwe activity of C on human aofffc 
vascular smooth muscle ceils [SMC], we tested the influence of C and of 
diff ~ ~_nt agents whc'h contnbute to C's activity. SMC were cultured under 
serum free conditions and either treated for 6 hm wffh different cor~-,,;,~- 
tions of C, C's metabofite BM 91.0228 IBM] [without ~.blocldng, but 30.fold 
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